NCT00294632View on ClinicalTrials.gov

Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

54

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions

Lymphoma

Interventions

DRUG

Lenalidomide

Starting Dose 10 mg By Mouth Daily on Days 1-21

DRUG

Rituximab

375 mg/m\^2 By Vein Weekly for 4 Weeks

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Celgene Corporation

All Listed Sponsors

collaborator

Celgene Corporation

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00294632 - Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma | Biotech Hunter | Biotech Hunter